Issue Date: January 16, 2006
Sankyo, KAI in cardiac pact
Daiichi Sankyo and KAI Pharmaceuticals have formed a licensing agreement under which the Japanese firm will obtain development rights to KAI-9803, a cardiovascular drug candidate in Phase II clinical trials. Sankyo will pay KAI $20 million and milestone payments of up to $300 million. KAI may receive $20 million from Sankyo in research support over five years to identify new compounds, routes of administration, and indications for cardiovascular therapies.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society